🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

875 results for “A.” Clear

  1. NORADRENALINA TARTRATO MONICO 2 mg/ml Concentrato per soluzione per infusione

    Pharma Mar S.A.

    criticall illness

    phase 3 small molecule active

    1 trial

  2. Nacubactam, Imipenem/Cilastatin Kabi 500 mg/500 mg Pulver zur Herstellung einer Infusionslösung, Cefepim PANPHARMA 2 g Pulver zur Herstellung einer Injektions- bzw. Infusionslösung, AZACTAM 1 g, poudre et solution pour usage parentéral

    Pharma Mar S.A.

    Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

  3. Nilemdo 180 mg film-coated tablets, Obicetrapib, Obicetrapib matching placebo, Bempedoic acid matching placebo

    Menarini International Operations Luxembourg S.A. (MIOL)

    Dyslipidemia at High to Very High Cardiovascular Risk

    phase 3 small molecule active

    1 trial

  4. Niraparib Placebo Tablets

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  5. Niraparib Placebo Tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  6. Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation, Sterile 0.9% (w/v) sodium chloride solution in single-use PFS

    GlaxoSmithKline Biologicals S.A.

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  7. OCA 5MG IR +BZF 400 MG SR

    Pharma Mar S.A.

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  8. OCA IR 0.1 mg, 0,1 mg and 1,5 mg Placebo tablets, OCA 1.5 mg

    Pharma Mar S.A.

    Biliary Atresia, Post-hepatoportoenterostomy

    phase 3 small molecule active

    1 trial

  9. OPDIVO 10 mg/mL concentrate for solution for infusion., TIVOZANIB, TIVOZANIB

    Pharma Mar S.A.

    Renal cell carcinoma

    phase 3 small molecule active

    1 trial

  10. Octaplex 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Octaplex 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

    Pharma Mar S.A.

    Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor

    phase 3 small molecule active

    1 trial

  11. PARACETAMOL , Dapirolizumab pegol, Placebo matching dapirolizumab pegol and without active substance, -, DIPHENHYDRAMINE , -, EPINEPHRINE , -, -

    Pharma Mar S.A.

    Systemic lupus erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  12. PEMBROLIZUMAB , Adagloxad simolenin with adjuvant, CAPECITABINE

    Pharma Mar S.A.

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  13. PL1 - Lyophilisate and solvent for solution for injection, sotatercept

    Pharma Mar S.A.

    Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  14. PLACEBO for GIVINOSTAT hydrochloride monohydrate (ITF2357) 10 mg/mL oral suspension, ITF2357

    Italfarmaco S.p.A.

    Duchenne muscular dystrophy (DMD)

    phase 3 small molecule active

    1 trial

  15. PREDNISOLONE , Dupixent 300 mg solution for injection in pre-filled syringe, Placebo matching to dupilumab

    Pharma Mar S.A.

    Bullous Pemphigoid

    phase 3 small molecule active

    1 trial

  16. PREDNISOLONE, Placebo for Depemokimab Injection, Placebo for Prednisolone

    GlaxoSmithKline Biologicals S.A.

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial

  17. PRIDOPIDINE, Pridopidine placebo

    Ferrer Internacional S.A.

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    1 trial

  18. PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  19. PSMA-11 kit for Ga-68 labelling

    Bial Portela & Companhia S.A.

    Intermediate and high-risk prostate cancer

    phase 3 small molecule active

    1 trial

  20. Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Armisarte 25 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion.

    Pharma Mar S.A.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  21. Paracetamol/Ibuprofen Vale 1000 mg/300 mg oldatos infúzió

    Pharma Mar S.A.

    Acute pain

    phase 3 small molecule active

    1 trial

  22. Placebo (Lisaftoclax), Lisaftoclax, Azacitidine Seacross 25 mg/mL powder for suspension for injection

    Pharma Mar S.A.

    Newly Diagnosed Higher Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  23. Placebo (Vehicle) for investigational DFL24498, Isocyclosporin A, DEXAMETHASONE

    Dompe' Farmaceutici S.p.A.

    Atopic Keratoconjunctivitis

    phase 3 small molecule active

    1 trial

  24. Placebo de formule développée spécifiquement pour la recherche par la PUI (cf IMPD-Q), CLOBETASOL PROPIONATE

    Pari Pharma GmbH

    Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources